Document is current

Any future updates will be listed below

LO-017 Zetomipzomib (KZR-616) demonstrates anti-inflammatory and immunomodulatory potential in patients with active lupus with or without lupus nephritis: results from the open-label Phase 1b/2 MISSION study

Crossref DOI link: https://doi.org/10.1136/lupus-2023-KCR.17

Published Online: 2023-08-06

Published Print: 2023-07

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark